What should I avoid while taking Maprotiline 75mg tablets?

Limit caffeine intake. Take with or without food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Maprotiline 75mg tablets?

Maprotiline 75mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Maprotiline 75mg tablets?

Maprotiline 75mg tablets is the generic name. It is available under brand names including: Ludiomil 75mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Maprotiline 75mg tablets

Tablet

75mg

Oral

Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs).

Active ingredients:

Maprotiline

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N06AA21

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Maprotiline

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Maprotiline

Source: MHRA Products DatabaseOGL 3.0

Updated 6 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Maprotiline

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Maprotiline

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Maprotiline on the MHRA register

Ludiomil 75mg tablets

Novartis Pharmaceuticals UK Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated 4 months ago(1 Mar 2026)

Daily dose

WHO defined daily dose (DDD)

100 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similar

Nortriptyline 25mg capsules

Capsule

25mg

Same therapeutic group

Nortriptyline 10mg capsules

Capsule

10mg

Same therapeutic group

Nortriptyline 10mg/5ml oral solution sugar free

Oral solution

10mg/5ml

Same therapeutic group

Nortriptyline 25mg/5ml oral solution sugar free

Oral solution

25mg/5ml

Same therapeutic group

Clomipramine 250mg/5ml oral suspension

Oral suspension

250mg/5ml

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42274011000001107

dm+d ID

42274011000001107

VTM (Virtual Therapeutic Moiety)

776633002

VMP (Virtual Medicinal Product)

42274011000001107

BNF code (NHS dm+d)

04030100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N06AA21

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 5 · 1977–2025

Sort

The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.

Pillinger T, Arumuham A, McCutcheon RA, et al.

2025

Systematic review

Open access

Cited by 16

Antidepressive Agents
Blood Pressure
Heart Rate

BackgroundAntidepressants induce physiological alterations; however, the degree to which these occur in treatment with various antidepressants is unclear. We aimed to compare and rank antidepressants based on physiological side-effects by synthesising data from randomised controlled trials (RCTs).MethodsWe searched MEDLINE, EMBASE, PsycINFO, ClinicalTrials.gov, and the US Food and Drug Administration (FDA) website from database inception to April 21, 2025. We included single-blinded and double-blinded RCTs comparing antidepressants and placebo in acute monotherapy of any psychiatric disorder. We did frequentist random-effects network meta-analyses to investigate treatment-induced changes in weight; total cholesterol; glucose; heart rate; systolic and diastolic blood pressure; corrected QT interval (QTc); sodium; potassium; aspartate transferase (AST); alanine transaminase (ALT); alkaline phosphatase (ALP); bilirubin; urea; and creatinine. We did meta-regressions to examine study-level associations between physiological change and age, sex, and baseline weight. We estimated the correlation between depressive symptom severity change and metabolic parameter change.FindingsOf 26 252 citations, 151 studies and 17 FDA reports met inclusion criteria. The overall sample included 58 534 participants, comparing 30 antidepressants with placebo. Median treatment duration was 8 weeks (IQR 6·0-8·5). We observed clinically significant differences between antidepressants in terms of metabolic and haemodynamic effects, including an approximate 4 kg difference in weight-change between agomelatine and maprotiline, over 21 beats-per-minute difference in heart rate change between fluvoxamine and nortriptyline, and over 11 mmHg difference in systolic blood pressure between nortriptyline and doxepin. Paroxetine, duloxetine, desvenlafaxine, and venlafaxine were associated with increases in total cholesterol and, for duloxetine, glucose concentrations, despite all drugs reducing bodyweight. There was strong evidence of duloxetine, desvenlafaxine, and levomilnacipran increasing AST, ALT, and ALP concentrations, although the magnitudes of these alterations were not considered clinically significant. We did not find strong evidence of any antidepressant affecting QTc, or concentrations of sodium, potassium, urea, and creatinine to a clinically significant extent. Higher baseline bodyweight was associated with larger antidepressant-induced increases in systolic blood pressure, ALT, and AST, and higher baseline age was associated with larger antidepressant-induced increases in glucose. We did not observe an association between changes in depressive symptoms and metabolic disturbance.InterpretationWe found strong evidence that antidepressants differ markedly in their physiological effects, particularly for cardiometabolic parameters. Treatment guidelines should be updated to reflect differences in physiological risk, but choice of antidepressant should be made on an individual basis, considering clinical presentation and preferences of patients, carers, and clinicians.FundingNational Institute for Health Research, Maudsley Charity, Wellcome Trust, Medical Research Council.

Abstract licence: CC BY

Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.

M. Dam, P. Tonin, A. Boni, et al.

Stroke, 1996

Cited by 333

Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: A double-blind comparative study with fluvoxamine and maprotiline.

T. Silverstone

International Clinical Psychopharmacology, 1988

Cited by 235

Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline

R. Muscat, M. Papp, P. Willner

Psychopharmacology, 2005

Cited by 192

Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile.

F. Martényi, M. Dossenbach, K. Mraz, et al.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2001

Cited by 161

A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics.

M. Vrethem, J. Boivie, H. Arnqvist, et al.

The Clinical journal of pain, 1997

Cited by 142

Metabolism of Some “Second”– and “Fourth”–Generation Antidepressants: Iprindole, Viloxazine, Bupropion, Mianserin, Maprotiline, Trazodone, Nefazodone, and Venlafaxine

Susan Rotzinger, M. Bourin, Y. Akimoto, et al.

Cellular and Molecular Neurobiology, 1999

Review

Cited by 54

Maprotiline: A Review of its Pharmacological Properties and Therapeutic Efficacy in Mental Depressive States

R. Pinder, R. N. Brogden, T. Speight, et al.

Drugs, 1977

Review

Cited by 36

The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug‐resistant Burkitt's lymphoma

S. Cloonan, David C. Williams

International Journal of Cancer, 2011

Cited by 98

Maprotiline, nomifensine, mianserin, zimelidine: A review of antidepressant efficacy in in-patients

S.A. Montgomery

Neuropharmacology, 1980

Review

Cited by 29

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

14 found

Half-life

51 hours

Mechanism

Maprotiline exerts its antidepressant action by inhibition of presynaptic uptake…

Food interactions

2 warnings

Human targets

13 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Slowly, but completely absorbed from the GI tract following oral administration.

Half-life

51 hours

Average ~ 51 hours (range: 27-58 hours)

Protein binding

88%

Volume of distribution

Maprotiline and its metabolites may be detected in the lungs, liver, brain, and kidneys; lower concentrations may be found in the adrenal glands, heart and muscle.…

Metabolism

Hepatic. Maprotiline is metabolized by N-demethylation, deamination, aliphatic and aromatic hydroxylations and by formation of aromatic methoxy derivatives.…

Elimination

60%

Approximately 60% of a single orally administered dose is excreted in urine as conjugated metabolites within 21 days; 30% is eliminated in feces.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.

Properties:

solid

Avg. mass: 277.40 Da

DrugBank indication

For treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis.

Also known as(77)

Maprotilina

Maprotiline

Maprotilinum

Maprotylina

NAT1

NET

NET1

Norepinephrine transporter

Molecular properties(18)

Drug interactions(2005)

Known interactions with other medications. Always consult a healthcare professional.

Deferasirox

Unknown severity

DB01609

The serum concentration of Maprotiline can be increased when it is combined with Deferasirox.

Check this interaction

Peginterferon alfa-2b

Unknown severity

DB00022

The serum concentration of Maprotiline can be increased when it is combined with Peginterferon alfa-2b.

Check this interaction

Leflunomide

Unknown severity

DB01097

The serum concentration of Maprotiline can be decreased when it is combined with Leflunomide.

Check this interaction

Teriflunomide

Unknown severity

DB08880

The serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide.

Check this interaction

Buprenorphine

Moderate

DB00921

Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.

Check this interaction

Hydrocodone

Moderate

DB00956

Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Maprotiline can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Maprotiline may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.

Check this interaction

Orphenadrine

Moderate

DB01173

Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.

Check this interaction

Pramipexole

Moderate

DB00413

Maprotiline may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Maprotiline may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Maprotiline may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Maprotiline.

Check this interaction

Sodium oxybate

Moderate

DB09072

Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.

Check this interaction

Thalidomide

Moderate

DB01041

Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Aclidinium

Unknown severity

DB08897

The risk or severity of adverse effects can be increased when Maprotiline is combined with Aclidinium.

Check this interaction

Mianserin

Moderate

DB06148

Mianserin may increase the anticholinergic activities of Maprotiline.

Check this interaction

Mirabegron

Unknown severity

DB08893

The risk or severity of urinary retention can be increased when Maprotiline is combined with Mirabegron.

Check this interaction

Potassium chloride

Unknown severity

DB00761

The risk or severity of gastrointestinal ulceration can be increased when Maprotiline is combined with Potassium chloride.

Check this interaction

Pramlintide

Unknown severity

DB01278

The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Maprotiline.

Check this interaction

Secretin porcine

Moderate

DB09527

The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Maprotiline.

Check this interaction

Tiotropium

Unknown severity

DB01409

The risk or severity of adverse effects can be increased when Maprotiline is combined with Tiotropium.

Check this interaction

Topiramate

Unknown severity

DB00273

The risk or severity of hyperthermia and oligohydrosis can be increased when Maprotiline is combined with Topiramate.

Check this interaction

Umeclidinium

Unknown severity

DB09076

The risk or severity of adverse effects can be increased when Maprotiline is combined with Umeclidinium.

Check this interaction

Benzylpenicilloyl polylysine

Moderate

DB00895

Maprotiline may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.

Check this interaction

Betahistine

Moderate

DB06698

The therapeutic efficacy of Betahistine can be decreased when used in combination with Maprotiline.

Check this interaction

Hyaluronidase (ovine)

Moderate

DB00070

The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Maprotiline.

Check this interaction

Hyaluronidase (human recombinant)

Moderate

DB06205

The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Maprotiline.

Check this interaction

Hyaluronidase

Moderate

DB14740

The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Maprotiline.

Check this interaction

Methadone

Unknown severity

DB00333

The risk or severity of adverse effects can be increased when Methadone is combined with Maprotiline.

Check this interaction

Glycopyrronium

Unknown severity

DB00986

The risk or severity of adverse effects can be increased when Maprotiline is combined with Glycopyrronium.

Check this interaction

Rasagiline

Unknown severity

DB01367

The risk or severity of adverse effects can be increased when Rasagiline is combined with Maprotiline.

Check this interaction

Pargyline

Unknown severity

DB01626

The risk or severity of adverse effects can be increased when Pargyline is combined with Maprotiline.

Check this interaction

Hydracarbazine

Unknown severity

DB09243

The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Maprotiline.

Check this interaction

Benmoxin

Unknown severity

DB09246

The risk or severity of adverse effects can be increased when Benmoxin is combined with Maprotiline.

Check this interaction

Mebanazine

Unknown severity

DB09248

The risk or severity of adverse effects can be increased when Mebanazine is combined with Maprotiline.

Check this interaction

Octamoxin

Unknown severity

DB09249

The risk or severity of adverse effects can be increased when Octamoxin is combined with Maprotiline.

Check this interaction

Pheniprazine

Unknown severity

DB09250

The risk or severity of adverse effects can be increased when Pheniprazine is combined with Maprotiline.

Check this interaction

Phenoxypropazine

Unknown severity

DB09251

The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Maprotiline.

Check this interaction

Showing 50 of 2005 interactions

Food & lifestyle interactions

Caffeine Notice

Limit caffeine intake.

Advice

Take with or without food.

Toxicity & overdose

LD₅₀=~900 mg/kg (Orally in rats); LD₅₀=90 mg/kg (Orally in women); Signs of overdose include motor unrest, muscular twitching and rigidity, tremor, ataxia, convulsions, hyperpyrexia, vertigo, mydriasis, vomiting, cyanosis, hypotension, shock, tachycardia, cardiac arrhythmias, impaired cardiac conduction, respiratory depression, and disturbances of consciousness up to deep coma.

How it works

Mechanism of action

Maprotiline exerts its antidepressant action by inhibition of presynaptic uptake of catecholamines, thereby increasing their concentration at the synaptic clefts of the brain. In single doses, the effect of maprotiline on the EEG revealed a rise in the alpha-wave density, a reduction of the alpha-wave frequency and an increase in the alpha-wave amplitude. However, as with other tricyclic antidepressants, maprotiline lowers the convulsive threshold. Maprotiline acts as an antagonist at central presynaptic α₂-adrenergic inhibitory autoreceptors and hetero-receptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity. Maprotiline is also a moderate peripheral α₁ adrenergic antagonist, which may explain the occasional orthostatic hypotension reported in association with its use. Maprotiline also inhibits the amine transporter, delaying the reuptake of noradrenaline and norepinephrine. Lastly, maprotiline is a strong inhibitor of the histamine H₁ receptor, which explains its sedative actions.

Pharmacodynamics

Maprotiline is a tetracyclic antidepressant. Although its main therapeutic use is in the treatment of depression, it has also been shown to exert a sedative effect on the anxiety component that often accompanies depression. In one sleep study, it was shown that maprotiline increases the duration of the REM sleep phase in depressed patients, compared to imipramine which reduced the REM sleep phase. Maprotiline is a strong inhibitor of noradrenaline reuptake in the brain and peripheral tissues, however it is worthy to note that it is a weak inhibitor of serotonergic uptake. In addition, it displays strong antihistaminic action (which may explain its sedative effects) as well as weak anticholinergic action. Maprotiline also has lower alpha adrenergic blocking activity than amitriptyline.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Slowly, but completely absorbed from the GI tract following oral administration.

Half-life

Average ~ 51 hours (range: 27-58 hours)

Protein binding

88%

Volume of distribution

Maprotiline and its metabolites may be detected in the lungs, liver, brain, and kidneys; lower concentrations may be found in the adrenal glands, heart and muscle. Maprotiline is readily distributed into breast milk to similar concentrations as those in maternal blood.

Metabolism

Hepatic. Maprotiline is metabolized by N-demethylation, deamination, aliphatic and aromatic hydroxylations and by formation of aromatic methoxy derivatives. It is slowly metabolized primarily to desmethylmaprotiline, a pharmacologically active metabolite.

Desmethylmaprotiline may undergo further metabolism to maprotiline-N-oxide.

Route of elimination

Approximately 60% of a single orally administered dose is excreted in urine as conjugated metabolites within 21 days; 30% is eliminated in feces.

Drug targets(13)

Proteins and enzymes this drug interacts with in the body

Sodium-dependent noradrenaline transporter

BE0000486

SLC6A2

inhibitor

Specific functionactin binding

Cellular location

Cell membrane

General function & pharmacology

Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signaling neurotransmitter in the autonomic sympathetic nervous system .
PMID:2008212 PMID:8125921 PMID:38750358

Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis (By similarity). Can also mediate sodium- and chloride-dependent transport of dopamine PMID:11093780 PMID:8125921 PMID:39395208 PMID:39048818

Histamine H1 receptor

BE0000442

HRH1

antagonist

Specific functionhistamine receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein-coupled receptor for histamine, a biogenic amine that functions as an immune modulator and a neurotransmitter .
PMID:33828102 PMID:8280179
Through the H1 receptor, histamine mediates the contraction of smooth muscles and increases capillary permeability due to contraction of terminal venules. Also mediates neurotransmission in the central nervous system and thereby regulates circadian rhythms, emotional and locomotor activities as well as cognitive functions (By similarity)

Muscarinic acetylcholine receptor M1

BE0000092

CHRM1

antagonist

Specific functionG protein-coupled acetylcholine receptor activity

Cellular location

Cell membrane

General function & pharmacology

Muscarinic acetylcholine receptor M2

BE0000560

CHRM2

antagonist

Specific functionarrestin family protein binding

Cellular location

Cell membrane

General function & pharmacology

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol

Muscarinic acetylcholine receptor M3

BE0000045

CHRM3

antagonist

Specific functionacetylcholine binding

Cellular location

Cell membrane

General function & pharmacology

Metabolizing enzymes(2)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP1A2Cytochrome P450 1A2

substrate

CYP2D6Cytochrome P450 2D6

substrate

Carriers(1)

Proteins that carry this drug through the body

Alpha-1-acid glycoprotein 1

BE0000925

ORM1

Cellular location

Secreted

General function & pharmacology

Functions as a transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body.

Appears to function in modulating the activity of the immune system during the acute-phase reaction

ATC classification(1 code)

ATC N06AA21

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Maprotiline hydrochloride(DBSALT000482)

Experimental properties(3)

External resources(1)

Drugs.com

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Maprotiline

DB00934

CAS number

10262-69-8

UNII (FDA)

2U1W68TROF

InChI Key (molecular fingerprint)

QSLMDECMDJKHMQ-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

2274

ChEBI

6690

PubChem Compound

4011

PubChem Substance

46508358

KEGG Compound

C07107

KEGG Drug

D02566

ChemSpider

3871

BindingDB

50101973

PharmGKB

PA450322

Therapeutic Targets Database

DAP001150

IUPHAR

2402

Guide to Pharmacology

2402

Wikipedia

Maprotiline

ChEMBL

CHEMBL21731

ZINC

ZINC000001530688

RxCUI

6646

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11048

GenAtlas

SLC6A2

GeneCards

SLC6A2

GenBank Gene Database

M65105

GenBank Protein Database

189258

Guide to Pharmacology

926

UniProtKB

P23975

UniProt Accession

SC6A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5182

GenAtlas

HRH1

GeneCards

HRH1

GenBank Gene Database

Z34897

GenBank Protein Database

510296

IUPHAR

262

Guide to Pharmacology

262

UniProtKB

P35367

UniProt Accession

HRH1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1950

GenAtlas

CHRM1

GeneCards

CHRM1

GenBank Gene Database

X52068

GenBank Protein Database

34451

IUPHAR

Guide to Pharmacology

UniProtKB

P11229

UniProt Accession

ACM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1951

GenAtlas

CHRM2

GeneCards

CHRM2

GenBank Gene Database

M16404

GenBank Protein Database

177990

IUPHAR

Guide to Pharmacology

UniProtKB

P08172

UniProt Accession

ACM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1952

GenAtlas

CHRM3

GeneCards

CHRM3

GenBank Gene Database

X15266

GenBank Protein Database

32324

IUPHAR

Guide to Pharmacology

UniProtKB

P20309

UniProt Accession

ACM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1953

GenAtlas

CHRM4

GeneCards

CHRM4

GenBank Gene Database

M16405

GenBank Protein Database

61970253

IUPHAR

Guide to Pharmacology

UniProtKB

P08173

UniProt Accession

ACM4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1954

GenAtlas

CHRM5

GeneCards

CHRM5

GenBank Gene Database

M80333

GenBank Protein Database

177988

IUPHAR

Guide to Pharmacology

UniProtKB

P08912

UniProt Accession

ACM5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:280

GenAtlas

ADRA1D

GeneCards

ADRA1D

GenBank Gene Database

M76446

GenBank Protein Database

177807

IUPHAR

Guide to Pharmacology

UniProtKB

P25100

UniProt Accession

ADA1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5302

GenAtlas

HTR7

GeneCards

HTR7

GenBank Gene Database

U68487

GenBank Protein Database

1857143

IUPHAR

Guide to Pharmacology

UniProtKB

P34969

UniProt Accession

5HT7R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:282

GenAtlas

ADRA2B

GeneCards

ADRA2B

GenBank Gene Database

M34041

GenBank Protein Database

178198

IUPHAR

Guide to Pharmacology

UniProtKB

P18089

UniProt Accession

ADA2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8498

GenAtlas

ORM1

GeneCards

ORM1

GenBank Gene Database

X02544

GenBank Protein Database

757907

UniProtKB

P02763

UniProt Accession

A1AG1_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 4 months ago(4 Mar 2026)

Structured knowledge from the free knowledge base

Q418361

Wikipedia article

chemical compound

Read on Wikipedia

WHO INN:maprotiline

International Nonproprietary Name

Research database identifiers

MeSH

D008376

ChEBI

CHEBI:6690

ATC classifications (Wikidata)

N06AA21

Linked open data from Wikidata (Q418361), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.

Source: Q418361CC0 1.0

Updated about 3 hours ago(5 Jul 2026)

Back to medicines

Maprotiline 75mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
16

Chemical identifiers

Maprotiline

Additional database identifiers

DrugBank citations

Wikipedia article

Research database identifiers

Maprotiline 75mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science16

Chemical identifiers

Maprotiline

Additional database identifiers

DrugBank citations

Wikidata linked open data

Wikipedia article

Research database identifiers

Deep science
16